Noqdirna (Desmopressin)

Desmopressin, the active ingredient in Noqdirna, is a vasopressin analog presented as a sublingual formulation for sublingual use. It is employed to manage central diabetes insipidus, nocturnal enuresis, and to support hemostasis in hemophilia A and von Willebrand disease.

GNH USA supplies Noqdirna as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides full regulatory documentation to support export to EU and other global markets, ensuring reliable delivery and compliance with local health authority requirements.

Desmopressin acts on the antidiuretic hormone pathway to control water balance and enhance clotting factor release. - Central diabetes insipidus: reduces excessive urine output by increasing renal water reabsorption. - Nocturnal enuresis: decreases nighttime bedwetting episodes by concentrating urine. - Hemophilia A (adjunct to factor VIII replacement): raises plasma factor VIII levels to improve clot formation. - Von Willebrand disease (type 1): elevates von Willebrand factor to aid hemostasis.

Desmopressin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate pain in the head. - Nausea: feeling of queasiness or upset stomach. - Nasal or oral irritation: mild burning or soreness at the sublingual site. - Facial flushing: transient redness of the face and neck. - Abdominal cramps: intermittent stomach discomfort. - Mild hyponatremia: slight reduction in blood sodium without symptoms.

Serious or Rare Side Effects: - Severe hyponatremia with seizures or coma: marked drop in sodium leading to neurologic compromise. - Water intoxication: excessive fluid retention causing edema, pulmonary congestion, or hyponatremic encephalopathy. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Thromboembolic events: clot formation leading to deep‑vein thrombosis or pulmonary embolism. - Hypotension: sudden drop in blood pressure causing dizziness or fainting.

Before initiating therapy, clinicians should consider several safety measures. - Monitor fluid intake: limit excessive water consumption to reduce hyponatremia risk. - Check serum sodium: assess baseline and periodic sodium levels during therapy. - Adjust dose in renal impairment: reduce dosage in patients with reduced kidney function. - Use caution in elderly: older adults are more susceptible to water retention and hyponatremia. - Avoid concomitant vasopressin antagonists: may diminish therapeutic effect. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Desmopressin can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Thiazide diuretics: potentiate antidiuretic effect, increasing hyponatremia risk. - Carbamazepine: enhances desmopressin clearance, reducing efficacy. - V2‑receptor antagonists (e.g., conivaptan): block therapeutic action.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of water retention and hyponatremia. - Anticoagulants (e.g., factor VIII concentrates): additive effect on clotting, monitor bleeding parameters. - SSRIs: potential additive effect on serotonin levels, observe for hyponatremia.